Olivia Blazek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olivia Blazek has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Angela L. Brown
Cardiovascular Division, Department of Medicine, Washington University in St. Louis, St Louis, Missouri, USA
1 shared publication - Antonio B. Fernandez
Hartford HealthCare, Hartford, CT
1 shared publication - Cara East
Jack and Jane Hamilton Heart and Vascular Hospital
1 shared publication - Carlos Mena-Hurtado
Yale School of Medicine
1 shared publication - Cassandra D. Ford
Capstone College of Nursing, University of Alabama , Tuscaloosa, Alabama
1 shared publication Etee Patel
Heart and Vascular Institute, Department of Medicine, Hartford HealthCare, Hartford, CT, USA
1 shared publication
Latest Publications
- 8 July 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 52, 102298
The safety and associated complications of cardiac stress testing in select populations
- 8 July 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 52, 102298
The safety and associated complications of cardiac stress testing in select populations
- Top Cited PapersOpen Access
- 1 October 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (10) , e135-e148
Renal Denervation for the Treatment of Hypertension: A Scientific Statement From the American Heart Association
Hypertension is a leading risk factor for cardiovascular morbidity and mortality. Despite the widespread availability of both pharmacological and lifestyle therapeutic options, blood pressure control rates across the globe are worsening. In fact, only 23% of individuals with high blood pressure in the United States achieve treatment goals. In 2023, the US Food and Drug Administration approved renal denervation, a catheter-based procedure that ablates the renal sympathetic nerves, as an adjunctive treatment for patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. This approval followed the publication of multiple randomized clinical studies using rigorous trial designs, all incorporating renal angiogram as the sham control. Most but not all of the new generation of trials reached their primary end point, demonstrating modest efficacy of renal denervation in lowering blood pressure across a spectrum of hypertension, from mild to truly resistant. Individual patient responses vary, and further research is needed to identify those who may benefit most. The initial safety profile appears favorable, and multiple ongoing studies are assessing longer-term efficacy and safety. Multidisciplinary teams that include hypertension specialists and adequately trained proceduralists are crucial to ensure that referrals are made appropriately with full consideration of the potential risks and benefits. Incorporating patient preferences and engaging in shared decision-making conversations will help patients make the best decisions given their individual circumstances. Although further research is clearly needed, renal denervation presents a novel treatment strategy for patients with uncontrolled blood pressure.
- 1 October 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (10) , e135-e148
Top Cited PapersOpen AccessRenal Denervation for the Treatment of Hypertension: A Scientific Statement From the American Heart Association
Hypertension is a leading risk factor for cardiovascular morbidity and mortality. Despite the widespread availability of both pharmacological and lifestyle therapeutic options, blood pressure control rates across the globe are worsening. In fact, only 23% of individuals with high blood pressure in the United States achieve treatment goals. In 2023, the US Food and Drug Administration approved renal denervation, a catheter-based procedure that ablates the renal sympathetic nerves, as an adjunctive treatment for patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. This approval followed the publication of multiple randomized clinical studies using rigorous trial designs, all incorporating renal angiogram as the sham control. Most but not all of the new generation of trials reached their primary end point, demonstrating modest efficacy of renal denervation in lowering blood pressure across a spectrum of hypertension, from mild to truly resistant. Individual patient responses vary, and further research is needed to identify those who may benefit most. The initial safety profile appears favorable, and multiple ongoing studies are assessing longer-term efficacy and safety. Multidisciplinary teams that include hypertension specialists and adequately trained proceduralists are crucial to ensure that referrals are made appropriately with full consideration of the potential risks and benefits. Incorporating patient preferences and engaging in shared decision-making conversations will help patients make the best decisions given their individual circumstances. Although further research is clearly needed, renal denervation presents a novel treatment strategy for patients with uncontrolled blood pressure.
- 4 October 2023
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 17 (6) , 748-755
Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease
- 4 October 2023
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 17 (6) , 748-755
Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease